SLC6A1 and Parkinson disease: The major finding of this study is that the GABA transporter 1 inhibitor tiagabine attenuates MPTP- and LPS-induced dopaminergic toxicity, inhibits microglial activation in vivo and improves motor behavior in PD mice.